Note 21 - Condensed Consolidating Financial Information Of Guarantor Subsidiaries (Tables)

12 Months Ended

May 31, 2013

Disclosure Text Block Supplement [Abstract]

Condensed Consolidating Balance Sheets [Table Text Block]

	Successor
	Immucor, Inc.		Guarantors			Non-Guarantors		Eliminations			Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	6,971		4,107			18,310		-			29,388
Accounts receivable, net		26,517		5,552			36,017		-			68,086
Intercompany receivable		54,443		7,961			4,313		(66,717	)		-
Inventories		18,551		15,897			12,978		(1,485	)		45,941
Deferred income tax assets, current portion		3,098		1,097			533		562			5,290
Prepaid expenses and other current assets		6,360		483			4,734		-			11,577
Total current assets		115,940		35,097			76,885		(67,640	)		160,282
PROPERTY AND EQUIPMENT, net		40,124		17,060			19,197		-			76,381
INVESTMENT IN SUBSIDIARIES		248,150		5,743			4		(253,897	)		-
GOODWILL		903,802		41,763			57,898		-			1,003,463
INTANGIBLE ASSETS, net		634,194		39,523			40,886					714,603
DEFERRED FINANCING COSTS		39,449		-			-		-			39,449
OTHER ASSETS		6,203		184			405		-			6,792
Total assets	$	1,987,862		139,370			195,275		(321,537	)		2,000,970
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	7,587		3,315			2,736		-			13,638
Intercompany payable		424		59,347			7,440		(67,211	)		-
Accrued expenses and other current liabilities		31,737		5,290			9,711		-			46,738
Income taxes payable		30,879		(30,457	)		3,451					3,873
Deferred revenue, current portion		1,086		6			1,160		-			2,252
Current portion of long-term debt, net of debt discounts		6,673		39			-		-			6,712
Total current liabilities		78,386		37,540			24,498		(67,211	)		73,213
LONG-TERM DEBT, net of debt discounts		1,039,250		28			-		-			1,039,278
DEFERRED REVENUE		62		-			99		-			161
DEFERRED INCOME TAX LIABILITIES		214,222		4,861			11,957					231,040
OTHER LONG-TERM LIABILITIES		11,236		114			1,222		-			12,572
Total liabilities		1,343,156		42,543			37,776		(67,211	)		1,356,264
SHAREHOLDERS' EQUITY:
Total shareholders' equity		644,706		96,827			157,499		(254,326	)		644,706
Total liabilities and shareholders' equity	$	1,987,862		139,370			195,275		(321,537	)		2,000,970

	Successor
	Immucor, Inc.		Guarantor		Non-Guarantors		Eliminations			Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	8,093		-		10,629		(144	)		18,578
Accounts receivable, net		27,542		489		38,361		-			66,392
Intercompany receivable		46,856		23		7,610		(54,489	)		-
Inventories		21,697		1,438		10,235					33,370
Deferred income tax assets, current portion		4,168		531		790		-			5,489
Prepaid expenses and other current assets		6,336		31,227		4,784		(30,609	)		11,738
Total current assets		114,692		33,708		72,409		(85,242	)		135,567
PROPERTY AND EQUIPMENT, net		44,103		1,407		19,152		-			64,662
INVESTMENT IN SUBSIDIARIES		162,895		-		4		(162,899	)		-
GOODWILL		903,512		6,659		56,167		-			966,338
INTANGIBLE ASSETS, net		682,187		10,438		42,897		-			735,522
DEFERRED FINANCING COSTS		38,769		-		-		-			38,769
OTHER ASSETS		7,817		5,558		370		(5,450	)		8,295
Total assets	$	1,953,975		57,770		190,999		(253,591	)		1,949,153
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	9,816		1,145		1,773		-			12,734
Intercompany payable		190		39,177		15,122		(54,489	)		-
Accrued expenses and other current liabilities		31,250		1,421		8,829		(144	)		41,356
Income taxes payable		30,719		-		3,544		(30,609	)		3,654
Deferred revenue, current portion		1,270		20		1,316		-			2,606
Current portion of long term debt, net of debt discounts		3,922		-		-		-			3,922
Total current liabilities		77,167		41,763		30,584		(85,242	)		64,272
LONG TERM DEBT, net of debt discounts		986,361		-		-		-			986,361
DEFERRED REVENUE		391		-		40		-			431
DEFERRED INCOME TAX LIABILITIES		238,582		-		12,364		(5,450	)		245,496
OTHER LONG-TERM LIABILITIES		14,096		-		1,119		-			15,215
Total liabilities		1,316,597		41,763		44,107		(90,692	)		1,311,775
SHAREHOLDERS' EQUITY:
Total shareholders' equity		637,378		16,007		146,892		(162,899	)		637,378
Total liabilities and shareholders' equity	$	1,953,975		57,770		190,999		(253,591	)		1,949,153

Condensed Consolidating Statements of Operations [Table Text Block]

	Successor
	Immucor, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
NET SALES	$	256,676			15,835			124,465			(49,188	)		347,788
COST OF SALES (exclusive of amortization shown separately below)		84,320			11,056			73,839			(49,188	)		120,027
GROSS MARGIN		172,356			4,779			50,626			-			227,761
OPERATING EXPENSES:
Research and development		13,428			7,850			35			-			21,313
Selling and marketing		25,611			3,632			20,886			-			50,129
Distribution		11,599			421			6,698			-			18,718
General and administrative		32,259			6,673			9,985			-			48,917
Amortization of intangibles		47,820			663			2,282			-			50,765
Loss on disposition of fixed assets		1,175			-			-			-			1,175
Total operating expenses		131,892			19,239			39,886			-			191,017
(LOSS) INCOME FROM OPERATIONS		40,464			(14,460	)		10,740			-			36,744
NON-OPERATING (EXPENSE) INCOME:
Interest income		-			-			97			(69	)		28
Interest expense		(90,875	)		(2	)		(22	)		69			(90,830	)
Loss on extinguishment of debt		(9,111	)		-			-			-			(9,111	)
Other, net		(1,043	)		(84	)		588			-			(539	)
Total non-operating (expense) income		(101,029	)		(86	)		663			-			(100,452	)
(LOSS) INCOME BEFORE INCOME TAXES		(60,565	)		(14,546	)		11,403			-			(63,708	)
(BENEFIT) PROVISION FOR INCOME TAXES		(23,783	)		(4,773	)		3,990			-			(24,566	)
NET (LOSS) INCOME BEFORE EARNINGS OF CONSOLIDATED SUBSIDIARIES		(36,782	)		(9,773	)		7,413			-			(39,142	)
Net (Loss) Income of consolidated subsidiaries		(2,360	)		-			-			2,360			-
NET (LOSS) INCOME	$	(39,142	)		(9,773	)		7,413			2,360			(39,142	)

	Successor
	Immucor, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
NET SALES	$	195,377			4,087			97,528			(35,178	)		261,814
COST OF SALES (exclusive of amortization shown separately below)		73,109			3,844			63,923			(35,178	)		105,698
GROSS MARGIN		122,268			243			33,605			-			156,116
OPERATING EXPENSES:
Research and development		7,724			6,113			92			-			13,929
Selling and marketing		17,868			1,654			13,391			-			32,913
Distribution		8,697			137			5,499			-			14,333
General and administrative		26,850			1,682			9,784			-			38,316
Amortization of intangibles		37,173			161			1,890			-			39,224
Certain litigation expenses		22,000			-			-			-			22,000
Total operating expenses		120,312			9,747			30,656			-			160,715
INCOME (LOSS) FROM OPERATIONS		1,956			(9,504	)		2,949			-			(4,599	)
NON-OPERATING (EXPENSE) INCOME:
Interest income		-			-			89			(82	)		7
Interest expense		(77,066	)		-			(64	)		82			(77,048	)
Other, net		406			-			41						447
Total non-operating (expense) income		(76,660	)		-			66			-			(76,594	)
(LOSS) INCOME BEFORE INCOME TAXES		(74,704	)		(9,504	)		3,015			-			(81,193	)
(BENEFIT) PROVISION FOR INCOME TAXES		(29,426	)		(3,275	)		1,155			-			(31,546	)
NET (LOSS) INCOME BEFORE EARNINGS OF CONSOLIDATED SUBSIDIARIES		(45,278	)		(6,229	)		1,860			-			(49,647	)
Net (Loss) Income of consolidated subsidiaries		(4,369	)		-			-			4,369			-
NET (LOSS) INCOME	$	(49,647	)		(6,229	)		1,860			4,369			(49,647	)

	Predecessor
	Immucor, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
NET SALES	$	55,063			980			26,648			(7,781	)		74,910
COST OF SALES (exclusive of amortization shown separately below)		17,070			722			12,944			(7,781	)		22,955
GROSS MARGIN		37,993			258			13,704			-			51,955
OPERATING EXPENSES:
Research and development		2,390			2,471			34			-			4,895
Selling and marketing		5,321			568			4,621			-			10,510
Distribution		2,331			34			1,587			-			3,952
General and administrative		33,903			657			3,615			-			38,175
Amortization of intangibles		117			757			57			-			931
Total operating expenses		44,062			4,487			9,914			-			58,463
(LOSS) INCOME FROM OPERATIONS		(6,069	)		(4,229	)		3,790			-			(6,508	)
NON-OPERATING (EXPENSE) INCOME:
Interest income		46			-			117			(21	)		142
Interest expense		-			-			(21	)		21			-
Other, net		(246	)		14			2,905			-			2,673
Total non-operating (expense) income		(200	)		14			3,001			-			2,815
(LOSS) INCOME BEFORE INCOME TAXES		(6,269	)		(4,215	)		6,791			-			(3,693	)
(BENEFIT) PROVISION FOR INCOME TAXES		1,497			(1,598	)		2,782			-			2,681
NET (LOSS) INCOME BEFORE EARNINGS OF CONSOLIDATED SUBSIDIARIES		(7,766	)		(2,617	)		4,009			-			(6,374	)
Net (Loss) Income of consolidated subsidiaries		1,392			-			-			(1,392	)		-
NET (LOSS) INCOME	$	(6,374	)		(2,617	)		4,009			(1,392	)		(6,374	)

	Predecessor
	Immucor, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
NET SALES	$	244,339		$	4,577		$	116,748		$	(32,573	)	$	333,091
COST OF SALES (exclusive of amortization shown separately below)		67,726			3,549			57,473			(32,573	)		96,175
GROSS MARGIN		176,613			1,028			59,275			-			236,916
OPERATING EXPENSES:
Research and development		6,815			8,925			160			-			15,900
Selling and marketing		17,265			1,919			17,247			-			36,431
Distribution		9,932			130			6,446			-			16,508
General and administrative		24,899			2,892			9,956			-			37,747
Amortization of intangibles		539			3,544			250			-			4,333
Total operating expenses		59,450			17,410			34,059			-			110,919
INCOME (LOSS) FROM OPERATIONS		117,163			(16,382	)		25,216			-			125,997
NON-OPERATING INCOME (EXPENSE):
Interest income		279			-			527			(100	)		706
Interest expense		(56	)		-			(114	)		100			(70	)
Other, net		(103	)		4,168			(68	)		-			3,997
Total non-operating income		120			4,168			345			-			4,633
INCOME (LOSS) BEFORE INCOME TAXES		117,283			(12,214	)		25,561			-			130,630
PROVISION (BENEFIT) FOR INCOME TAXES		42,051			(8,721	)		7,973			-			41,303
NET INCOME (LOSS) BEFORE EARNINGS OF CONSOLIDATED SUBSIDIARIES		75,232			(3,493	)		17,588			-			89,327
Net Income (Loss) of consolidated subsidiaries		14,095			-			-			(14,095	)		-
NET INCOME (LOSS)	$	89,327		$	(3,493	)	$	17,588		$	(14,095	)	$	89,327

Condensed Consolidating Cash Flow Information [Table Text Block]

	Successor
	Immucor, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
Net cash provided by (used in) operating activities	$	4,690			6,423			13,534			(113	)		24,534
Net cash used in investing activities		(86,490	)		(2,164	)		(5,747	)		-			(94,401	)
Net cash provided by ( used in) financing activities		80,840			(8	)		-			-			80,832
Effect of exchange rate changes on cash and cash equivalents		(162	)		-			(106	)		113			(155	)
(Decrease) increase in cash and cash equivalents		(1,122	)		4,251			7,681			-			10,810
Cash and cash equivalents at beginning of period		8,093			(144	)		10,629			-			18,578
Cash and cash equivalents at end of period	$	6,971			4,107			18,310			-			29,388

	Successor
	Immucor, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
Net cash provided by (used in) operating activities	$	(15,073	)	$	903		$	18,080		$	(13,503	)	$	(9,593	)
Net cash used in investing activities		(1,943,229	)		(814	)		(1,407	)	$	-			(1,945,450	)
Net cash provided by ( used in) financing activities		1,652,091			-			(14,003	)	$	14,002			1,652,090
Effect of exchange rate changes on cash and cash equivalents		-			-			(789	)	$	(643	)		(1,432	)
Increase (decrease) in cash and cash equivalents		(306,211	)		89			1,881			(144	)		(304,385	)
Cash and cash equivalents at beginning of period		314,304			(89	)		8,748			-			322,963
Cash and cash equivalents at end of period	$	8,093		$	-		$	10,629			(144	)	$	18,578

	Predecessor
	Immucor, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
Net cash provided by (used in) operating activities	$	64,243		$	144		$	(13,821	)	$	(24,978	)	$	25,588
Net cash used in investing activities		(393	)		(153	)		(1,719	)		-			(2,265	)
Net cash provided by (used in) financing activities		68			-			(25,085	)		25,083			66
Effect of exchange rate changes on cash and cash equivalents		-			-			(2,924	)		(105	)		(3,029	)
Increase (decrease) in cash and cash equivalents		63,918			(9	)		(43,549	)		-			20,360
Cash and cash equivalents at beginning of period		250,386			(80	)		52,297			-			302,603
Cash and cash equivalents at end of period	$	314,304		$	(89	)	$	8,748		$	-		$	322,963

	Predecessor
	Immucor, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
Net cash provided by operating activities	$	82,767		$	803		$	17,731		$	810		$	102,111
Net cash used in investing activities		(6,112	)		(605	)		(2,344	)		-			(9,061	)
Net cash provided by financing activities		2,578			-			-			-			2,578
Effect of exchange rate changes on cash and cash equivalents		9			-			5,127			(810	)		4,326
Increase in cash and cash equivalents		79,242			198			20,514			-			99,954
Cash and cash equivalents at beginning of period		171,144			(278	)		31,783			-			202,649
Cash and cash equivalents at end of period	$	250,386		$	(80	)	$	52,297		$	-		$	302,603